6Senol G, Erbaycu A, Ozsoz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother, 2005,17 : 380-384,
7Rodriguez JC, Cebrian L, Ruiz M, et al. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis. Chemotherapy, 2005,51 : 76-79.
8Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis, 2002,6 : 164-165.
9Lenaerts AM, Chase SE, Cynamon MH. Evaluation of rifalazil in a combination treatmant regimen as an alternative to isoniazidrifampin therapy in a mouse tuberculosis model. Antimicrob Agents Chemother , 2000 , 44 : 3167- 3168.
10Dietze R, Teixeira L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.Antimicrob Agents Chemother,2001,45 1972-1976.
7Centers for Disease Control and Prevention (CDC). Emergence of mycobaeterium tuberculosis with extensive resistance to second line drugs-worldwide 2000-2004[J]. MMWR Morb Mortal Wkly Rep,2006,55( 11) :301-305.
8Centers for Disease Control and Prevention (CDC). Extensively drug resistant tuberculosis United States, 1993 2006[J]. MMWR Morb Mortal Wkly Rep,2007,56(11):250-253.
9National Department of Health. Management of drug-resistant tuberculosis [M]. South Africa: National Department of Health,2010.
10Malaysia Health Technology Assessment Section, Medical De- velopment Division, Ministry of Health Malaysia. Management of Tuberculosis [M]. 3rd ed. Putrajaya, Malaysia: Malaysia Health Technology Assessment Section,2012:68.
